178 related articles for article (PubMed ID: 34273445)
1. Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing.
Chou S; Watters M; Sinha R; Kleiboeker S
Antiviral Res; 2021 Sep; 193():105139. PubMed ID: 34273445
[TBL] [Abstract][Full Text] [Related]
2. Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection.
Chou S; Wu J; Song K; Bo T
Antiviral Res; 2019 Dec; 172():104616. PubMed ID: 31568799
[TBL] [Abstract][Full Text] [Related]
3. Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo.
Chou S; Hakki M; Villano S
Antiviral Res; 2012 Aug; 95(2):88-92. PubMed ID: 22664236
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.
Chou S; Ercolani RJ; Marousek G; Bowlin TL
Antimicrob Agents Chemother; 2013 Jul; 57(7):3375-9. PubMed ID: 23650173
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance.
Chou S; Wechel LC; Marousek GI
J Infect Dis; 2007 Jul; 196(1):91-4. PubMed ID: 17538888
[TBL] [Abstract][Full Text] [Related]
6. Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants.
Chou S; Watanabe J
Antiviral Res; 2024 Feb; 222():105792. PubMed ID: 38163624
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
Chou S
Rev Med Virol; 2008; 18(4):233-46. PubMed ID: 18383425
[TBL] [Abstract][Full Text] [Related]
8. Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir.
Boutolleau D; Burrel S; Agut H
Antiviral Res; 2011 Jul; 91(1):32-5. PubMed ID: 21570426
[TBL] [Abstract][Full Text] [Related]
9. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
Chou S; Marousek GI
J Virol; 2008 Jan; 82(1):246-53. PubMed ID: 17942550
[TBL] [Abstract][Full Text] [Related]
10. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
Chou S; Alain S; Cervera C; Chemaly RF; Kotton CN; Lundgren J; Papanicolaou GA; Pereira MR; Wu JJ; Murray RA; Buss NE; Fournier M
J Infect Dis; 2024 Feb; 229(2):413-421. PubMed ID: 37506264
[TBL] [Abstract][Full Text] [Related]
11. Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.
Santos Bravo M; Plault N; Sánchez Palomino S; Mosquera Gutierrez MM; Fernández Avilés F; Suarez Lledo M; Sabé Fernández N; Rovira M; Alain S; Marcos Maeso MÁ
J Infect Dis; 2021 Sep; 224(6):1024-1028. PubMed ID: 33475730
[TBL] [Abstract][Full Text] [Related]
12. Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection.
Chou S; Song K; Wu J; Bo T; Crumpacker C
J Infect Dis; 2022 Sep; 226(4):576-584. PubMed ID: 32726419
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir.
Chou S; Marousek GI; Senters AE; Davis MG; Biron KK
J Virol; 2004 Jul; 78(13):7124-30. PubMed ID: 15194788
[TBL] [Abstract][Full Text] [Related]
14. Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene.
Chou S; Ercolani RJ; Vanarsdall AL
J Clin Microbiol; 2017 Jul; 55(7):2098-2104. PubMed ID: 28446569
[TBL] [Abstract][Full Text] [Related]
15. Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir.
McGregor A; Choi KY; Cui X; McVoy MA; Schleiss MR
Antiviral Res; 2008 Jun; 78(3):250-9. PubMed ID: 18325607
[TBL] [Abstract][Full Text] [Related]
16. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.
Chou S; Marousek GI
Antimicrob Agents Chemother; 2006 Oct; 50(10):3470-2. PubMed ID: 17005835
[TBL] [Abstract][Full Text] [Related]
17. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
Chou S
Antimicrob Agents Chemother; 2009 Jan; 53(1):81-5. PubMed ID: 18981262
[TBL] [Abstract][Full Text] [Related]
18. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
Drew WL; Miner RC; Marousek GI; Chou S
J Clin Virol; 2006 Oct; 37(2):124-7. PubMed ID: 16962820
[TBL] [Abstract][Full Text] [Related]
19. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.
Chou S
Antimicrob Agents Chemother; 2010 Jun; 54(6):2371-8. PubMed ID: 20385869
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir.
Chou S; Waldemer RH; Senters AE; Michels KS; Kemble GW; Miner RC; Drew WL
J Infect Dis; 2002 Jan; 185(2):162-9. PubMed ID: 11807689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
